The more bulky, high affinity DARPin should remain in the outer layers of tumor nodules, where HER2 expression is reduced by the trastuzumab treatment, and thereby, their binding would be lower in comparison with the binding to non-treated tumor core. Here, ERBB2 is linked to neoplasm.